C9070 — Injection, tafasitamab-cxix, 2 mg
C9070 is a HCPCS Level II code for injection, tafasitamab-cxix, 2 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on March 31, 2021 and is not valid on new claims.
This code has been terminated
CMS terminated C9070 on March 31, 2021. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9070
- Long descriptor
- Injection, tafasitamab-cxix, 2 mg
- Short descriptor
- Injection, tafasitamab-cxix
- Added
- January 1, 2021
- Terminated
- March 31, 2021
- BETOS
- O1D
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9070
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9070 is not quite right, the correct code is very often within a few positions of it.
- C9062Injection, daratumumab 10 mg and hyaluronidase-fihjterminated
- C9063Injection, eptinezumab-jjmr, 1 mgterminated
- C9064Mitomycin pyelocalyceal instillation, 1 mgterminated
- C9065Injection, romidepsin, non-lyophilized (e.g. liquid), 1mgterminated
- C9066Injection, sacituzumab govitecan-hziy, 2.5 mgterminated
- C9067Gallium ga-68, dotatoc, diagnostic, 0.01 mci
- C9068Copper cu-64, dotatate, diagnostic, 1 millicurieterminated
- C9069Injection, belantamab mafodontin-blmf, 0.5 mgterminated
- C9071Injection, viltolarsen, 10 mgterminated
- C9072Injection, immune globulin (asceniv), 500 mgterminated
- C9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9074Injection, lumasiran, 0.5 mgterminated
- C9075Injection, casimersen, 10 mgterminated
- C9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9077Injection, cabotegravir and rilpivirine, 2mg/3mgterminated
- C9078Injection, trilaciclib, 1 mgterminated
Questions about C9070
What is HCPCS code C9070?
C9070 is a HCPCS Level II code for injection, tafasitamab-cxix, 2 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9070?
The CMS HCPCS file marks C9070 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9070 still valid?
No. C9070 was terminated on March 31, 2021 and should not be used on new claims.